Skip to main content
HANGZHOU BIOTEST BIOTECH CO.,LTD. logo

HANGZHOU BIOTEST BIOTECH CO.,LTD. — Investor Relations & Filings

Ticker · 688767 ISIN · CNE1000050H0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 452 across all filing types
Latest filing 2026-05-15 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688767

About HANGZHOU BIOTEST BIOTECH CO.,LTD.

https://en.biotests.com.cn/

Hangzhou Biotest Biotech Co., Ltd. specializes in the research, development, and manufacturing of rapid diagnostic test kits. The company focuses on in vitro diagnostics through lateral flow immunoassay technology. Its product portfolio includes tests for infectious diseases, drugs of abuse, oncology, cardiac markers, and fertility. Biotest provides solutions for clinical laboratories, hospitals, and point-of-care settings. The company maintains rigorous quality control systems and holds various international certifications to ensure the reliability of its diagnostic tools.

Recent filings

Filing Released Lang Actions
博拓生物2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 12% confidence The document is an official announcement of the 2025 annual shareholders’ meeting resolutions, showing attendance, voting breakdown, and results for each proposal. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-15 Chinese
博拓生物关于2024年员工持股计划预留股份第一个锁定期届满暨解锁条件成就的提示性公告
Regulatory Filings Classification · 65% confidence The document is a formal Shanghai Stock Exchange announcement concerning the expiration of lock-up periods and unlock conditions for an employee shareholding plan. It does not contain financial statements or detailed financial analysis, nor is it the actual annual or interim report, earnings release, governance code, or specific proxy/solicitation materials. It is also not a straightforward share issue or buyback announcement. This type of disclosure is a routine regulatory filing by the listed company, fitting the catch-all category for miscellaneous compliance announcements.
2026-05-15 Chinese
博拓生物关于股份回购进展公告
Regulatory Filings
2026-05-06 Chinese
博拓生物关于召开2025年年度股东会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2025 Annual General Meeting (AGM) of Hangzhou Botuo Biotechnology Co., Ltd. It includes information about the meeting date, voting methods, agenda items to be discussed and voted on, shareholder attendance, and proxy voting instructions. The document does not contain the actual annual report or financial statements but rather the announcement and procedural details for the upcoming AGM. The document length is 3363 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2026-04-24 Chinese
博拓生物关于2025年年度利润分配方案及2026年中期分红规划的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2025 annual profit distribution plan and the 2026 interim dividend plan. It details the dividend amount per share, the total dividend payout, and the conditions for the dividend distribution. It also mentions that the plan requires shareholder approval. The document does not contain full financial statements or comprehensive financial performance data but focuses on dividend distribution details. The length is 2549 characters, which is relatively short and typical for a dividend announcement. This fits the definition of a Notice of Dividend Amount (DIV) rather than a full Annual Report or Interim Report. Therefore, the appropriate classification is DIV.
2026-04-24 Chinese
2025年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a 2025年度审计报告 (2025 Annual Audit Report) for 杭州博拓生物科技股份有限公司, issued by a certified accounting firm (中汇). It contains detailed audit opinions, basis for audit, key audit matters, management responsibilities, and auditor responsibilities. It also includes comprehensive financial statements such as consolidated balance sheet, income statement, cash flow statement, and statement of changes in equity for the year ended December 31, 2025. The presence of an auditor's opinion and detailed financial statements indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it contains actual financial data and audit details, not just an announcement or certification. Therefore, the document fits the definition of an Audit Report / Information (AR).
2026-04-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.